Brachytherapy for oral tongue cancer: An analysis of treatment results with various biological markers

Japanese Journal of Clinical Oncology

Volumn 38, Issue 6, 2008, Pages 402-407

  Sakata, Koh ichi ^a   Someya, Masanori ^a   Nagakura, Hisayasu ^a   Nakata, Kensei ^a   Oouchi, Atushi ^a   Takagi, Masaru ^a   Hareyama, Masato ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brachytherapy; CA IX; Ki 67; Microvessel density; Tongue cancer

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE; GLUCOSE TRANSPORTER 1; MONOCLONAL ANTIBODY KI 67; CA9 PROTEIN, HUMAN; KI 67 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TONGUE CANCER; CHEMISTRY; GENE EXPRESSION REGULATION; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PREDICTION AND FORECASTING; TONGUE TUMOR; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BRACHYTHERAPY; CARBONIC ANHYDRASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 46349085980     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn050     Document Type: Article

References (29)

1. Benk V, Mazeron JJ, Grimard L, Crook J, Haddad E, Piedbois P, et al. Comparison of curietherapy versus external irradiation combined with curietherapy in stage II squamous cell carcinomas of the mobile tongue. Radiother Oncol 1990;18:339-47.
2. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, et al. Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: Factors influencing local control and soft tissue complications. Int J Radial Oncol Biol Phys 1999;44:767-75.
3. Shibuya H, Hoshina M, Takeda M, Matsumoto S, Suzuki S, Okada N. Brachytherapy for stage I & II oral tongue cancer: An analysis of past cases focusing on control and complications. Int J Radial Oncol Biol Phys 1993;26:51-8.
4. Zelefsky MJ, Valicenti RY, Goodman K, Perez CA. Prostate Cancer. In: Perez CA, Brady LW, Halperin EC, et al. editors. Principles and Practice of Radiation Oncology, 4th edn. Philadelphia: Lippincott Williams & Wilkins 2004; 1692-762.
5. Hall EJ. Repair of Radiation Damage and the Dose-ratc Effect. Radiobiology for the Radiologist. 5th edn. Philadelphia: Lippincott Williams & Wilkins 2000;67-90.
6. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, et al. An analysis of mandibular bone complications in radiotherapy for T1 and T2 carcinoma of the oral tongue. Int J Radiat Oncol Biol Phys 1996;34:333-9.
7. Paterson R, Parker HM. A dosage system for interstitial radium therapy. Br J Radiol 1952;25:505-16.
8. Sakata K, Someya M, Nagakura H, Nakata K, Oouchii A, Hareyama M, et al. A clinical study of hypoxia using endogenous hypoxic markers and polarographic oxygen electrodes. Strahlenther Onkol 2006;182:511-7.
9. Hironaka S, Hasebe T, Kamijo T, Ohtsu A, Boku N, Yoshida S, et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002;8:124-30.
10. Kamijo T, Yokose T, Hasebe T, Yonou H, Sasaki S, Hayashi R, et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res 2000;6:3159-65.
11. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001;7:3399-403.
12. Cox DR. Regression models and life tables. J R Stat Sor [B] 1972;34:187-220.
13. Masunaga S, Ono K, Abe M. A method for the selective measurement of the radiosensitivity of quiescent cells in solid tumors - combination of immunofluorescence staining to BrdU and micronucleus assay. Radiat Res 1991;125:243-7.
14. Mendonca MS, Rodriguez A, Alpen EL. Quiescence, in 9L cells and correlation with radiosensitivity and PLD repair. Radiat Res 1989;117:433-47.
15. Rodriguez A, Alpen EL, Mendonca M, DeGuzman RJ. Recovery from potentially lethal damage and recruitment time of noncycling clonogenic cells in 9L confluent monolayers and spheroids. Radiat Res 1988;114:515-27.
16. Masunaga S, Ono K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J Radiat Res (Tokyo) 2002;43:11-25.
17. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil RA, Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J. Clin Oncol 1997;15:1030-8.
18. Okuno Y, Nishimura Y, Kashu I, Ono K, Hiraoka M. Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki- 67 for radiotherapy of oesophageal squamous cell carcinomas. Br J Cancer 1999;80:387-95.
19. Nakano T, Oka K. Differential values of Ki-67 index and mitotic index of proliferating cell population: An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 1993;72:2401-8.
20. Weiss C, Rodel F, Wolf I, Papadopoulos T, Engehausen DG, Schrott KM, et al. Combined-modality treatment and organ preservation in bladder cancer: Do molecular markers predict outcome? Strahlenther Onkol 2005;181:213-22.
21. Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, et al. Dynamic echo-planar imaging of the breast: Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205:837-42.
22. Secomb TW, Hsu R, Dewhirst MW, Klitzman B, Gross JF. Analysis of oxygen transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys 1993;25:481-9.
23. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36: 1625-32.
24. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia (New York) 2001;3:80-7.
25. Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 1996;33:480-7.
26. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-11.
27. De Schutter H, Landuyt W, Verbeken E, Goethals L, Harmans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005;5:42.
28. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8: 2595-604.
29. Inoue T, Inoue T, Yoshida K, Yoshioka Y, Shimamoto S, Tanaka E, et al. Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. Inter J Radiat Oncol Biol Phys 2001:51:171-5.